



2007-09-20

PRESSRELEASE

Great interests for Oasmia in Budapest

Last week Oasmia Pharmaceutical AB presented the results from a phase I/II study with Paclical® Vet at the Veterinary European ECVIM-CA Congress in Budapest.

- The information about Oasmias new product has through the congress reached a greater public. Several leading veterinary clinics in Europe look forward to see Paclical® Vet on the market. There is a huge need of the product, says Kristina Fritjofsson, Head of Clinical Development at Oasmia.

More information is available at www.ngm.se or www.oasmia.com
Media contact: Maria Lundén +46 (0) 18 50 54 40 e-mail: info@oasmia.com

Oasmia Pharmaceutical is a pharmaceutical company that specialises in the treatment of severe diseases. A pharmaceutical company based on the latest concepts in bio-organic chemistry. The main idea is to improve the treatment of serious diseases. Primarily, this development is in oncology and treatment with cytostatics but Oasmia also conducts research in antibiotics, asthma and neurological diseases. Oasmia has in-house production capacity of pharmaceuticals for clinical trials, both company related and others. Oasmia has developed several products based on existing pharmaceuticals in a new environment, which leads to whole new solutions for cancer treatment. These products give Oasmia a solid product portfolio within oncology with several products in clinical or pre-clinical phase. Oasmia is listed on NGM Equity.